2114-P: Use of Visceral Fat Area Measurement for Evaluating Obesity in Elderly Patients with Type 2 Diabetes

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 2114-P
Author(s):  
TAKUYA MINAMIZUKA ◽  
YUKARI MAEDA ◽  
MASAYA KOSHIZAKA ◽  
TAKAHIRO ISHIKAWA ◽  
YOSHIRO MAEZAWA ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Elderly Patients ◽  
Visceral Fat ◽  
Area Measurement ◽  
Visceral Fat Area

scholarly journals Sodium-glucose Co-transporter 2 Inhibitors Reduce the Abdominal Visceral Fat Area and May Influence the Renal Function in Patients with Type 2 Diabetes

2017 ◽  
Vol 56 (6) ◽  
pp. 597-604 ◽  
Author(s):  
Takahiro Tosaki ◽  
Hideki Kamiya ◽  
Tatsuhito Himeno ◽  
Yoshiro Kato ◽  
Masaki Kondo ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Renal Function ◽  
Visceral Fat ◽  
Visceral Fat Area ◽  
Abdominal Visceral Fat

Gender differences of visceral fat area for predicting incident type 2 diabetes in Koreans

2018 ◽  
Vol 146 ◽  
pp. 93-100 ◽  
Author(s):  
Eun Hee Kim ◽  
Hong-Kyu Kim ◽  
Sung-Jin Bae ◽  
Min Jung Lee ◽  
Jenie Yoonoo Hwang ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Gender Differences ◽  
Visceral Fat ◽  
Visceral Fat Area ◽  
Incident Type ◽  
Incident Type 2 Diabetes

scholarly journals The Use of Continuous Glucose Monitoring System in Combination with Individualized Lifestyle and Therapeutic Recommandations on Glycemic Control of Type 2 Diabetes Patients

2014 ◽  
Vol 21 (4) ◽  
pp. 291-299
Author(s):  
Anca-Elena Crăciun ◽  
Cornelia Bala ◽  
Cristian Crăciun ◽  
Gabriela Roman ◽  
Carmen Georgescu ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Weight Gain ◽  
Glycemic Control ◽  
Insulin Therapy ◽  
Body Fat ◽  
Visceral Fat ◽  
Glucose Monitoring ◽  
Visceral Fat Area

Abstract Background and aims. The aim of our research was to evaluate the impact of short-time continuous glucose monitoring (CGM) on glycemic control evaluated by HbA1c and within-day glucose variability. We also assessed if the initiation of insulin therapy in conjunction with lifestyle recommendations may prevent the weight gain. Materials and method. We included 28 patients with type 2 diabetes with 2 consecutive CGMS recordings available (baseline and follow-up) and for which were collected data on weight, body mass index (BMI), percentage (%) of body fat, visceral fat area, HbA1c and glycemic variability. Results. The HbA1c decreased significantly from 8.8% at baseline to 7.3% at follow-up (p <0.0001) in the whole group, and from 10.5% to 7.5% in the subgroup for which the insulin therapy was initiated at baseline (p=0.011). The BMI, % body fat and visceral fat area decreased significantly from 29.2 kg/m2 to 28.4 kg/m2; from 32.3% to 30.4%; and from 141.6 to 129.3 (cm2), respectively. No increase of these parameters was observed in the subgroup for which the insulin therapy was initiated at baseline. Conclusion. The use of CGMS in combination with individualized lifestyle and therapeutic recommendations may have a beneficial effect on glycemic control and may prevent the weight gain associated with insulin initiation.

Sign in / Sign up

Export Citation Format

Share Document